Surgery Partners (SGRY) Stock Forecast & Price Target

Compare

380 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SGRY Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Surgery

Partners

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SGRY Stock 12 Month Forecast

Average Price Target

$20.31

▲(64.02% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Surgery Partners in the last 3 months. The average price target is $20.31 with a high forecast of $33.00 and a low forecast of $14.00. The average price target represents a 64.02% change from the last price of $12.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","34":"$34","18.25":"$18.25","23.5":"$23.5","28.75":"$28.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.305555555555557,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,18.25,23.5,28.75,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.88,17.196923076923078,18.513846153846153,19.83076923076923,21.147692307692306,22.464615384615385,23.78153846153846,25.098461538461535,26.415384615384614,27.732307692307693,29.049230769230768,30.366153846153843,31.683076923076918,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.88,16.22042735042735,16.5608547008547,16.901282051282053,17.241709401709404,17.582136752136755,17.922564102564102,18.262991452991454,18.603418803418805,18.943846153846156,19.284273504273507,19.624700854700855,19.965128205128206,{"y":20.305555555555557,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.88,15.735384615384616,15.590769230769231,15.446153846153846,15.301538461538462,15.156923076923077,15.012307692307694,14.867692307692309,14.723076923076924,14.57846153846154,14.433846153846154,14.28923076923077,14.144615384615385,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.88,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$33.00

Average Price Target$20.31

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

A.J. Rice

UBS

$29→$21

Buy

69.63%

Upside

Reiterated

03/10/26

Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN)

Brian Tanquilut

Jefferies

$16.25

Buy

31.26%

Upside

Reiterated

03/05/26

Analysts Are Bullish on Top Healthcare Stocks: Surgery Partners (SGRY), Stryker (SYK)

Ann Hynes

Mizuho Securities

$19→$17

Buy

37.32%

Upside

Reiterated

03/05/26

Surgery Partners price target lowered to $17 from $19 at MizuhoSurgery Partners price target lowered to $17 from $19 at Mizuho

Ryan Langston

TD Cowen

$28→$20

Buy

61.55%

Upside

Assigned

03/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Surgery Partners (NASDAQ: SGRY) and Keros Therapeutics (NASDAQ: KROS)

Bill Sutherland

Benchmark Co.

$30→$24

Buy

93.86%

Upside

Reiterated

03/04/26

Surgery Partners price target lowered to $24 from $30 at BenchmarkSurgery Partners price target lowered to $24 from $30 at Benchmark

Ben Hendrix

RBC Capital

$31→$20

Buy

61.55%

Upside

Reiterated

03/03/26

RBC Capital Remains a Buy on Surgery Partners (SGRY)

Joanna Gajuk

Bank of America Securities

$24→$17.5

Buy

41.36%

Upside

Reiterated

03/03/26

Surgery Partners price target lowered to $17.50 from $24 at BofASurgery Partners price target lowered to $17.50 from $24 at BofA

Andrew Mok CFA

Barclays

$14

Hold

13.09%

Upside

Reiterated

03/03/26

Surgery Partners (SGRY) Receives a Hold from Barclays

Sarah James

Cantor Fitzgerald

$33

Buy

166.56%

Upside

Reiterated

03/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Benjamin Rossi

J.P. Morgan

$27→$20

Hold

61.55%

Upside

Reiterated

11/24/25

Surgery Partners price target lowered to $20 from $27 at JPMorganSurgery Partners price target lowered to $20 from $27 at JPMorgan

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

11/11/25

Wall Street Analysts Are Neutral on Top Healthcare Picks

Whit Mayo

Leerink Partners

$34

Buy

174.64%

Upside

Reiterated

08/06/25

Leerink Partners Reaffirms Their Buy Rating on Surgery Partners (SGRY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

A.J. Rice

UBS

$29→$21

Buy

69.63%

Upside

Reiterated

03/10/26

Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN)

Brian Tanquilut

Jefferies

$16.25

Buy

31.26%

Upside

Reiterated

03/05/26

Analysts Are Bullish on Top Healthcare Stocks: Surgery Partners (SGRY), Stryker (SYK)

Ann Hynes

Mizuho Securities

$19→$17

Buy

37.32%

Upside

Reiterated

03/05/26

Surgery Partners price target lowered to $17 from $19 at MizuhoSurgery Partners price target lowered to $17 from $19 at Mizuho

Ryan Langston

TD Cowen

$28→$20

Buy

61.55%

Upside

Assigned

03/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Surgery Partners (NASDAQ: SGRY) and Keros Therapeutics (NASDAQ: KROS)

Bill Sutherland

Benchmark Co.

$30→$24

Buy

93.86%

Upside

Reiterated

03/04/26

Surgery Partners price target lowered to $24 from $30 at BenchmarkSurgery Partners price target lowered to $24 from $30 at Benchmark

Ben Hendrix

RBC Capital

$31→$20

Buy

61.55%

Upside

Reiterated

03/03/26

RBC Capital Remains a Buy on Surgery Partners (SGRY)

Joanna Gajuk

Bank of America Securities

$24→$17.5

Buy

41.36%

Upside

Reiterated

03/03/26

Surgery Partners price target lowered to $17.50 from $24 at BofASurgery Partners price target lowered to $17.50 from $24 at BofA

Andrew Mok CFA

Barclays

$14

Hold

13.09%

Upside

Reiterated

03/03/26

Surgery Partners (SGRY) Receives a Hold from Barclays

Sarah James

Cantor Fitzgerald

$33

Buy

166.56%

Upside

Reiterated

03/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Benjamin Rossi

J.P. Morgan

$27→$20

Hold

61.55%

Upside

Reiterated

11/24/25

Surgery Partners price target lowered to $20 from $27 at JPMorganSurgery Partners price target lowered to $20 from $27 at JPMorgan

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

11/11/25

Wall Street Analysts Are Neutral on Top Healthcare Picks

Whit Mayo

Leerink Partners

$34

Buy

174.64%

Upside

Reiterated

08/06/25

Leerink Partners Reaffirms Their Buy Rating on Surgery Partners (SGRY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Surgery Partners

3 Months

xxx

Success Rate

15/28 ratings generated profit

Average Return

+6.87%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.57% of your transactions generating a profit, with an average return of +6.87% per trade.

1 Year

Brian TanquilutJefferies

Success Rate

11/28 ratings generated profit

Average Return

+9.10%

a rating ―

Copying Brian Tanquilut's trades and holding each position for 1 Year would result in 39.29% of your transactions generating a profit, with an average return of +9.10% per trade.

2 Years

xxx

Success Rate

6/28 ratings generated profit

Average Return

-6.51%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 21.43% of your transactions generating a profit, with an average return of -6.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SGRY Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SGRY has received 9 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SGRY average Analyst price target in the past 3 months is 20.31.

Each month's total comprises the sum of three months' worth of ratings.

SGRY Financial Forecast

SGRY Earnings Forecast

Next quarter’s earnings estimate for SGRY is -$0.12 with a range of -$0.24 to -$0.02. The previous quarter’s EPS was $0.12. SGRY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year SGRY has Performed in-line its overall industry.

SGRY Sales Forecast

Next quarter’s sales forecast for SGRY is $797.32M with a range of $790.65M to $807.40M. The previous quarter’s sales results were $885.00M. SGRY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year SGRY has Performed in-line its overall industry.

SGRY Stock Forecast FAQ

What is SGRY’s average 12-month price target, according to analysts?

Based on analyst ratings, Surgery Partners Inc’s 12-month average price target is 20.31.

What is SGRY’s upside potential, based on the analysts’ average price target?

Surgery Partners Inc has 64.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SGRY a Buy, Sell or Hold?

Surgery Partners Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Surgery Partners Inc’s price target?

The average price target for Surgery Partners Inc is 20.31. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $33.00 ,the lowest forecast is $14.00. The average price target represents 64.02% Increase from the current price of $12.38.

What do analysts say about Surgery Partners Inc?

Surgery Partners Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of SGRY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Surgery Partners (SGRY) Stock Forecast & Price Target

SGRY Analyst Ratings

SGRY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Surgery Partners

SGRY Analyst Recommendation Trends

SGRY Financial Forecast

SGRY Earnings Forecast

SGRY Sales Forecast

SGRY Stock Forecast FAQ

Detailed List of Analyst Forecasts